{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:10:55Z","timestamp":1792001455818,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3\/UH3DA050311"],"award-info":[{"award-number":["UG3\/UH3DA050311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3DA054785"],"award-info":[{"award-number":["UG3DA054785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.phrs.2023.107023","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T11:35:01Z","timestamp":1702121701000},"page":"107023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders"],"prefix":"10.1016","volume":"199","author":[{"given":"Piyusha P.","family":"Pagare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Flammia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.107023_bib1","series-title":"Opioid Use Disorder","author":"Dydyk","year":"2023"},{"key":"10.1016\/j.phrs.2023.107023_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.phrs.2023.107023_bib3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12913-019-4751-4","article-title":"Opioid use disorder and treatment: challenges and opportunities","volume":"19","author":"Hoffman","year":"2019","journal-title":"BMC Health Serv. Res"},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib4","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/jacs.8b09756","article-title":"Chemical interventions for the opioid crisis: key advances and remaining challenges","volume":"141","author":"Olson","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2023.107023_bib5","article-title":"Drug overdose deaths in the United States, 1999\u20132018. NCHS Data Brief, no 356. Hyattsville","author":"Hedegaard","year":"2020","journal-title":"MD: Natl. Cent. Health Stat."},{"key":"10.1016\/j.phrs.2023.107023_bib6","unstructured":"National Institute on Drug Abuse. Drug Overdose Death Rates. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates (Accessed 10 September 2023)."},{"key":"10.1016\/j.phrs.2023.107023_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.phrs.2023.107023_bib8","first-page":"e836","article-title":"Opioid-associated out-of-hospital cardiac arrest: distinctive clinical features and implications for health care and public responses: a scientific statement from the american heart association","volume":"143","author":"Dexfulian","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2023.107023_bib10","unstructured":"CDC. Understanding the Opioid Overdose Epidemic. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html (Accessed 10 September 2023)."},{"key":"10.1016\/j.phrs.2023.107023_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2023.107023_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1176\/appi.ajp.20230273","article-title":"Fentanyl and other opioid use disorders: treatment and research needs","volume":"180","author":"Volkow","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2023.107023_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-030-81147-1_4","article-title":"The Brain\u2019s reward system in health and disease","volume":"1344","author":"Lewis","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2023.107023_bib15","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jcpt.13114","article-title":"Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management","volume":"45","author":"Pergolizzi","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2023.107023_bib18","unstructured":"Medications for Substance Use Disorders. https:\/\/www.samhsa.gov\/medications-substance-use-disorders (Accessed 10 September 2023)."},{"key":"10.1016\/j.phrs.2023.107023_bib19","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2","author":"Mattick","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2023.107023_bib20","first-page":"CD003409","article-title":"Methadone at tapered doses for the management of opioid withdrawal","volume":"3","author":"Amato","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2023.107023_bib22","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9776","key":"10.1016\/j.phrs.2023.107023_bib23","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2023.107023_bib24","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3\u20134","key":"10.1016\/j.phrs.2023.107023_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00952997509005662","article-title":"Clinical experience with naltrexone","volume":"2","author":"O\u2019Brien","year":"1975","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.phrs.2023.107023_bib26","series-title":"Naltrexone. In StatPearls","author":"Singh","year":"2023"},{"key":"10.1016\/j.phrs.2023.107023_bib27","unstructured":"FDA. VIVITROL\u00ae (naltrexone for extended-release injectable suspension) Intramuscular. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021897s015lbl.pdf. (accessed 14 November 2023)."},{"issue":"7","key":"10.1016\/j.phrs.2023.107023_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/1060028019828954","article-title":"Lofexidine: A newly FDA-approved, nonopioid treatment for opioid withdrawal","volume":"53","author":"Doughty","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.phrs.2023.107023_bib29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00213-022-06125-5","article-title":"Treatment of opioid overdose: current approaches and recent advances","volume":"239","author":"Britch","year":"2022","journal-title":"Psychopharmacol. (Berl."},{"issue":"2","key":"10.1016\/j.phrs.2023.107023_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone treatment in opioid addiction: the risks and benefits","volume":"6","author":"van Dorp","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.phrs.2023.107023_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/jpet.118.256115","article-title":"Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose","volume":"371","author":"Krieter","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7398","key":"10.1016\/j.phrs.2023.107023_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u039c-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"issue":"7565","key":"10.1016\/j.phrs.2023.107023_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u039c-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"7711","key":"10.1016\/j.phrs.2023.107023_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the \u039c-opioid receptor-Gi protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.phrs.2023.107023_bib35","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","article-title":"Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor","volume":"185","author":"Zhuang","year":"2022","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.phrs.2023.107023_bib36","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1359-6446(04)03220-9","article-title":"Allosteric modulation of G protein-coupled receptors: perspectives and recent developments","volume":"9","author":"Soudijn","year":"2004","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.phrs.2023.107023_bib37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acschemneuro.7b00090","article-title":"Recent advances in the realm of allosteric modulators for opioid receptors for future therapeutics","volume":"8","author":"Remesic","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2023.107023_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bcp.2010.12.012","article-title":"Strategies for the identification of allosteric modulators of g-protein-coupled receptors","volume":"81","author":"Burford","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","article-title":"Bridging the gap: bitopic ligands of G\u2013protein-coupled receptors","volume":"34","author":"Lane","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"26","key":"10.1016\/j.phrs.2023.107023_bib40","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.2174\/1568026619666191009164609","article-title":"Recent advances in the drug discovery and development of dualsteric\/ bitopic activators of g protein-coupled receptors","volume":"19","author":"Reinecke","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"14","key":"10.1016\/j.phrs.2023.107023_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200169","article-title":"Opioid ligands addressing unconventional binding sites and more than one opioid receptor subtype","volume":"17","author":"Drakopoulos","year":"2022","journal-title":"ChemMedChem"},{"issue":"18","key":"10.1016\/j.phrs.2023.107023_bib42","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.3390\/molecules25184257","article-title":"Biased opioid ligands","volume":"25","author":"Faouzi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.107023_bib43","series-title":"Opioid Antagonists","author":"Theriot","year":"2023"},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib44","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/jm801272c","article-title":"Design, synthesis, and biological evaluation of 6\u03b1- and 6\u03b2-N-heterocyclic substituted naltrexamine derivatives as \u03bc opioid receptor selective antagonists","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.phrs.2023.107023_bib45","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1016\/j.bmc.2013.08.042","volume":"21","author":"Zaidi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2023.107023_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2018.03.013","article-title":"In Vitro and in Vivo functional profile characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(Isoquinoline-3-Carboxamido)Morphinan (NAQ) as a low efficacy mu opioid receptor modulator","volume":"827","author":"Obeng","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2023.107023_bib47","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1124\/dmd.111.038588","article-title":"Preclinical disposition (in Vitro) of novel \u03bc-opioid receptor selective antagonists","volume":"39","author":"Mitra","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2023.107023_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuropharm.2019.03.020","article-title":"Role of agonist efficacy in exposure-induced enhancement of Mu opioid reward in rats","volume":"151","author":"Moerke","year":"2019","journal-title":"Neuropharmacol"},{"issue":"4","key":"10.1016\/j.phrs.2023.107023_bib49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00213-014-3719-7","article-title":"Effects of the novel, selective and low-efficacy Mu opioid receptor ligand NAQ on intracranial self-stimulation in rats","volume":"232","author":"Altarifi","year":"2015","journal-title":"Psychopharmacol. (Berl."},{"key":"10.1016\/j.phrs.2023.107023_bib50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2019.01.020","article-title":"Effectiveness comparisons of G-protein biased and unbiased Mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats","volume":"150","author":"Schwienteck","year":"2019","journal-title":"Neuropharmacol"},{"issue":"11","key":"10.1016\/j.phrs.2023.107023_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/acsptsci.2c00178","article-title":"Preclinical characterization and development on NAQ as a Mu opioid receptor partial agonist for opioid use disorder treatment","volume":"5","author":"Pagare","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"18","key":"10.1016\/j.phrs.2023.107023_bib52","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1016\/j.bmcl.2013.07.043","volume":"23","author":"Yuan","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.phrs.2023.107023_bib53","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bmc.2015.02.055","article-title":"Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(Isoquinoline-3\u2019-Carboxamido)morphinan analogues as opioid receptor ligands","volume":"23","author":"Yuan","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2023.107023_bib54","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1021\/acs.jmedchem.2c00087","article-title":"Design, synthesis, and biological evaluation of NAP isosteres: a switch from peripheral to central nervous system acting mu-opioid receptor antagonists","volume":"65","author":"Pagare","year":"2022","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.phrs.2023.107023_bib55","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1021\/jm4012214","article-title":"Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu\/kappa opioid receptor dual selectivity","volume":"56","author":"Yuan","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2023.107023_bib56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/acs.jmedchem.8b01158","article-title":"Design, synthesis, and biological evaluation of the third generation 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-Epoxy-6\u03b2-[(4\u2019-Pyridyl)Carboxamido]Morphinan (NAP) derivatives as \u03bc\/\u03ba Opioid Receptor Dual Selective Ligands","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.107023_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104702","article-title":"Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5\u03b1-epoxy-3,14\u03b2-dihydroxy-6\u03b2-[(4\u2019-Pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors","volume":"109","author":"Huang","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib58","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejpain.2005.02.002","article-title":"Interaction of Mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice","volume":"9","author":"K\u00f6gel","year":"2005","journal-title":"Eur. J. Pain."},{"issue":"22","key":"10.1016\/j.phrs.2023.107023_bib59","doi-asserted-by":"crossref","first-page":"9868","DOI":"10.1021\/jm301096s","article-title":"Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible \u03bc opioid receptor antagonist","volume":"55","author":"Moynihan","year":"2012","journal-title":"Eff.. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200432","article-title":"3-[3-(Phenalkylamino)Cyclohexyl]phenols: synthesis, biological activity, and in silico investigation of a naltrexone-derived novel class of MOR-antagonists","volume":"356","author":"Tocco","year":"2023","journal-title":"Arch. Pharm. (Weinh."},{"issue":"4","key":"10.1016\/j.phrs.2023.107023_bib61","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.3390\/ijms24043351","article-title":"Inhibitory effects of a novel \u03bc-opioid receptor nonpeptide antagonist, UD-030, on morphine-induced conditioned place preference","volume":"24","author":"Ide","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2023.107023_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2023.107023_bib63","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001185","article-title":"Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl","author":"Bird","year":"2023","journal-title":"J. Addict. Med."},{"issue":"12","key":"10.1016\/j.phrs.2023.107023_bib64","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jpain.2014.08.010","article-title":"The Fentanyl Story","volume":"15","author":"Stanley","year":"2014","journal-title":"J. Pain."},{"issue":"8","key":"10.1016\/j.phrs.2023.107023_bib65","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/bja\/52.8.795","article-title":"Pharmacokinetics of high-dose fentanyl. a study in patients undergoing cardiac surgery","volume":"52","author":"Bovill","year":"1980","journal-title":"Br. J. Anaesth."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone dosage for opioid reversal: current evidence and clinical implications","volume":"9","author":"Rzasa Lynn","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib67","article-title":"Higher doses of naloxone are needed in the synthetic opioid era","volume":"14","author":"Moss","year":"2019","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"issue":"2","key":"10.1016\/j.phrs.2023.107023_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1039\/D1MD00285F","article-title":"Design, synthesis, and biological evaluation of c6-difluoromethylenated epoxymorphinan mu opioid receptor antagonists","volume":"13","author":"Kassick","year":"2022","journal-title":"RSC Med. Chem."},{"issue":"21","key":"10.1016\/j.phrs.2023.107023_bib69","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1021\/acschemneuro.2c00464","article-title":"Opioid antagonists from the orvinol series as potential reversal agents for opioid overdose","volume":"13","author":"Disney","year":"2022","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib70","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jnr.24624","article-title":"Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse","volume":"100","author":"Kiguchi","year":"2022","journal-title":"J. Neurosci. Res."},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib71","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2023.107023_bib72","first-page":"99","article-title":"\u2212)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens","volume":"456","author":"Pertwee","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.phrs.2023.107023_bib73","doi-asserted-by":"crossref","first-page":"9466","DOI":"10.1021\/acs.jmedchem.3c00061","article-title":"Structure\u2013activity relationship study of cannabidiol-based analogs as negative allosteric modulators of the \u03bc-opioid receptor","volume":"66","author":"Bosquez-Berger","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2023.107023_bib74","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.106.113167","article-title":"Allosteric interactions at the Mu-opioid receptor","volume":"320","author":"Rothman","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2023.107023_bib75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0026-895X(25)13145-3","article-title":"Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods","volume":"33","author":"Ehlert","year":"1988","journal-title":"Mol. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2023.107023_bib76","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/1087057114542975","article-title":"Identification of selective agonists and positive allosteric modulators for \u039c- and \u03b4-opioid receptors from a single high-throughput screen","volume":"19","author":"Burford","year":"2014","journal-title":"SLAS Discov."},{"issue":"26","key":"10.1016\/j.phrs.2023.107023_bib77","doi-asserted-by":"crossref","first-page":"10830","DOI":"10.1073\/pnas.1300393110","article-title":"Discovery of positive allosteric modulators and silent allosteric modulators of the \u03bc-opioid receptor","volume":"110","author":"Burford","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"51","key":"10.1016\/j.phrs.2023.107023_bib78","doi-asserted-by":"crossref","first-page":"18369","DOI":"10.1073\/pnas.1415013111","article-title":"Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the Mu-Opioid receptor","volume":"111","author":"Livingston","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.phrs.2023.107023_bib79","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000017118","article-title":"Positive allosteric modulation of the Mu-opioid receptor produces analgesia with reduced side effects","volume":"118","author":"Kandasamy","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"S3","key":"10.1016\/j.phrs.2023.107023_bib80","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1124\/jpet.122.180140","article-title":"Positive allosteric modulation of the Mu opioid receptor does not potentiate opioid-mediated side effects","volume":"385","author":"Kochan","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2023.107023_bib81","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1021\/acs.jcim.5b00388","article-title":"Ligand-based discovery of a new scaffold for allosteric modulation of the \u03bc-opioid receptor","volume":"55","author":"Bisignano","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.phrs.2023.107023_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108673","article-title":"A promising chemical series of positive allosteric modulators of the \u03bc-opioid receptor that enhance the antinociceptive efficacy of opioids but not their adverse effects","volume":"195","author":"Pryce","year":"2021","journal-title":"Neuropharmacol"},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jphs.2018.04.002","article-title":"Neuropeptide oxytocin enhances \u03bc opioid receptor signaling as a positive allosteric","volume":"137","author":"Meguro","year":"2018","journal-title":"Modul.. J. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2023.107023_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170901","article-title":"The first structure-activity relationship study of oxytocin as a positive allosteric modulator for the \u00b5 opioid receptor","volume":"159","author":"Mizuguchi","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2023.107023_bib85","doi-asserted-by":"crossref","first-page":"31748","DOI":"10.1038\/srep31748","article-title":"Ignavine: a novel allosteric modulator of the \u03bc opioid receptor","volume":"6","author":"Ohbuchi","year":"2016","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.phrs.2023.107023_bib86","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/jm500159d","article-title":"Putative Kappa opioid heteromers as targets for developing analgesics free of adverse effects","volume":"57","author":"Le Naour","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2023.107023_bib87","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/acschemneuro.8b00349","article-title":"Structure\u2212activity relationship studies of 6\u03b1- and 6\u03b2-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the \u201cmessage-address concept\u201d to comprehend their functional conversion","volume":"10","author":"Obeng","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib88","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1021\/acschemneuro.9b00038","article-title":"Characterization of 17-cyclopropylmethyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(Indole-7-Carboxamido)Morphinan (NAN) as a novel opioid receptor modulator for opioid use disorder treatment","volume":"10","author":"Obeng","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"24","key":"10.1016\/j.phrs.2023.107023_bib89","first-page":"11399","article-title":"Application of bivalent bioisostere concept on design and discovery","volume":"62","author":"Ma","year":"2019","journal-title":"Potent Opioid Recept. Modul. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.107023_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127953","article-title":"Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor","volume":"41","author":"Ma","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.phrs.2023.107023_bib91","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/acs.jmedchem.2c01499","article-title":"Structural alterations of the \u201caddress\u201d moiety of NAN leading to the discovery of a novel opioid receptor modulator with reduced hERG toxicity","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"issue":"7945","key":"10.1016\/j.phrs.2023.107023_bib92","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41586-022-05588-y","article-title":"S. Structure-based design of bitopic ligands for the \u00b5-opioid receptor","volume":"613","author":"Faouzi","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.phrs.2023.107023_bib93","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HRP.0000000000000271","article-title":"Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments","volume":"28","author":"Connery","year":"2020","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.phrs.2023.107023_bib95","unstructured":"National Institute on Drug Abuse. Naloxone Drug Facts. https:\/\/nida.nih.gov\/publications\/drugfacts\/naloxone (Accessed 10 September 2023)."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:48:09Z","timestamp":1760914089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823003791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":92,"alternative-id":["S1043661823003791"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.107023","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.107023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107023"}}